Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,280 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: COVID-19, Viral Respiratory Illnesses
Interventions: Nitazoxanide, Placebo, Vitamin Super B-Complex; Drug · Dietary Supplement
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 55 Years to 120 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Kissimmee, Florida • Acworth, Georgia • Lake Charles, Louisiana + 1 more

Conditions: HIV, Sexually Transmitted Diseases, HIV Infections
Interventions: DVD 1, DVD 2; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 16 Years and older
Enrollment: 1,010 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Malaria
Interventions: BNT165c, BNT165d, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more

Conditions: Influenza A
Interventions: Influenza A H7N7 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Sore-throat, Dysphonia, Dysphagia, Intubation Complication, Anesthesia Intubation Complication, Anesthesia Morbidity, Anesthesia Complication, Anesthesia; Adverse Effect, Anesthesia; Reaction, Throat Disorder, Throat; Wound, Throat Injury
Interventions: EndoClip; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Bacillus Anthracis (Anthrax)
Interventions: BioThrax®; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more

Conditions: Influenza
Interventions: CD388 Injection, Placebo; Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 63 Years
Enrollment: 5,071 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 56
States / cities: Anniston, Alabama • Cullman, Alabama • Tempe, Arizona + 51 more

Conditions: HIV-infection/Aids
Interventions: Cognitive-behavioral HIV/STD risk reduction; Behavioral
Lead sponsor: Mississippi State University; Other
Eligibility: 13 Years to 18 Years · Female only
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Columbia, Mississippi

Conditions: Leukemia, Lymphoma, Graft Versus Host Disease
Interventions: cyclosporine, cyclosporine and methotrexate; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 9 more

Conditions: Prophylaxis of A/H3N2v Influenza
Interventions: Swine Influenza; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 3 Years to 92 Years
Enrollment: 627 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Redding, California • Sacramento, California • Lenexa, Kansas + 8 more

Conditions: COVID-19, Vitamin D Deficiency, Respiratory Viral Infection
Interventions: Daily Vitamin D3, Daily placebo, Bolus vitamin D3, Bolus placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 50 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV-infection/AIDS
Interventions: Cultural adaptation of a patient-provider communication tool; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Rabies
Interventions: Chloroquine, Atovaquone and Proguanil, Doxycycline, Rabies Vaccine; Drug · Biological
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4); Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 1,500,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oakland, California

Conditions: HIV/AIDS, Menopause, Inflammation Vagina
Interventions: Tenofovir, Emtricitabine; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Participants
Interventions: Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo; Biological · Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 49 Years
Enrollment: 710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Prosthetic-joint Infection
Interventions: PLG0206, Placebo; Drug
Lead sponsor: Peptilogics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Sarasota, Florida • Tamarac, Florida • Shreveport, Louisiana + 13 more

Conditions: Clostridium Difficile Infection (CDI)
Interventions: RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence); Drug
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 60
States / cities: Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 25
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 15 more

Conditions: Lung Transplant Infection
Interventions: Tolsura; Drug
Lead sponsor: Hong Nguyen; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 1, Human Papilloma Virus Infection
Interventions: placebo, defined green tea catechin extract, laboratory biomarker analysis; Drug · Dietary Supplement · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: HIV Infections, Sexually Transmitted Infections
Interventions: Male Sexual Health Program, Focus on the Future Program; Behavioral
Lead sponsor: Richard Crosby; Other
Eligibility: 15 Years to 23 Years · Male only
Enrollment: 840 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Allogeneic Hematopoietic Stem Cell
Interventions: fecal microbiota transplantation (FMT), No fecal microbiota transplantation (FMT), routine management; Biological · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Diarrhea
Interventions: Heat-Labile Enterotoxin of Escherichia coli (LT), Placebo; Biological
Lead sponsor: Intercell USA, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more

Search by objective public record fields.

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

No Post Intubation Laryngeal Symptoms

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

Healthy Teen Girls: HIV Risk Reduction

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

Evaluation of Tolsura When Used as Prophylaxis After Lung Transplantation

Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia

HIV Prevention Program for African American Teen Males

Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

ETEC Logistics Trial (TREK)